Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain

Cantenys-Molina, Sergi; Fernández‐Cruz, Eduardo; Francos, P; Quirós, Jimena Crespo; Muñóz, Patricia; Gil-Herrera, Juana

doi:10.1111/cei.13547

Cited by 37 publications

(37 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, lymphocyte increment by one unit decreases the risk of death by 10% among COVID-19 hospitalized patients. This finding is supported by studies conducted in Italy, 76 Mexico, 90 Spain, 91 France, 40 and Wuhan. 92 Studies showed that as COVID-19 clinical stages advance, the lymphocyte count decreases, 93–95 thus, as the clinical stages of COVID-19 patients advance to severe and critical, the clinical outcome could be bad.…”

Section: Discussionsupporting

confidence: 63%

Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia

Ayana¹,

Merga²,

Birhanu³

et al. 2021

IDR

View full text Add to dashboard Cite

Background The very unprecedented virus causing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued causing catastrophes in economy and loss of human lives. Despite countries’ urgent and resilient public health actions against the COVID-19 pandemic, the disease is causing a large number of deaths. However, predictors of mortality among hospitalized COVID-19 patients have not been well investigated in Ethiopia. Therefore, this study aimed to identify the predictors of mortality among hospitalized COVID-19 patients at a tertiary care hospital in Ethiopia. Methods A hospital-based retrospective cohort design study was implemented among hospitalized COVID-19 patients at a tertiary care hospital in Harar, Ethiopia from March 20 to August 20, 2021. Data of 531 admitted patients were entered using Epi-data 3.1 and exported to STATA 14.2 for analysis. Binary logistic regression was used to identify significant predictors of outcome variables with an adjusted odds ratio (AOR) with a 95% confidence interval. Results Of the total 531 study participants, 101 deaths occurred. The mortality rate was 16.2 per 1000 person-days of observation with median survival time of 44 days with IQR [28, 74]. Smoking history [AOR=2.55, 95% CI (1.15, 5.65)], alcohol history [AOR=2.3, 95% CI (1.06, 4.97)], comorbidities [AOR=2.95, 95% CI (1.26, 6.91)], and increasing oxygen saturation [AOR=0.92, 95% CI (0.89, 0.95)], and lymphocyte count [AOR=0.90, 95% CI (0.88, 0.97)] were independent significant predictors of death from Covid-19. Conclusion The incidence of mortality among hospitalized COVID-19 patients was found to be high. Devising individual, tailored management for patients with “risk” behaviors, comorbid conditions, and poor prognostic markers such as lymphopenia and low oxygen saturation, may reduce the incidence of death among hospitalized COVID-19 patients.

show abstract

Section: Discussionsupporting

confidence: 63%

Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia

Ayana¹,

Merga²,

Birhanu³

et al. 2021

IDR

View full text Add to dashboard Cite

show abstract

“…These results were consistent with the study conducted in Spain, which demonstrated that there were no differences in CD19 + B cell percentages between the survivor and non-survivor groups 42 . The plausible explanation for this discrepancy may be due to the direct infection of T lymphocytes by SARS-CoV-2, cytokine-mediated lymphocyte trafficking into infected tissues, or lymphocyte exhaustion in the peripheral blood 42 , 43 . All of these hypotheses remain to be proven in further investigations.…”

Section: Discussionmentioning

confidence: 99%

A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19

Tang

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The 2019 Coronavirus Disease (COVID-19) has become an unprecedented public crisis. We retrospectively investigated the clinical data of 197 COVID-19 patients and identified 88 patients as disease aggravation cases. Compared with patients without disease aggravation, the aggravation cases had more comorbidities, including hypertension (25.9%) and diabetes (20.8%), and presented with dyspnoea (23.4%), neutrophilia (31.5%), and lymphocytopenia (46.7%). These patients were more prone to develop organ damage in liver, kidney, and heart (P < 0.05). A multivariable regression analysis showed that advanced age, comorbidities, dyspnea, lymphopenia, and elevated levels of Fbg, CTnI, IL-6, and serum ferritin were significant predictors of disease aggravation. Further, we performed a Kaplan–Meier analysis to evaluate the prognosis of COVID-19 patients, which suggested that 64.9% of the patients had not experienced ICU transfers and survival from the hospital.

show abstract

“…Cantenys-Molina et al [28] demonstrated that significant reduction of CD3 + CD4 + T cell percentages was associated with mortality and insignificant variations in CD19 + B cell percentages. However, no significant reduction was detected in CD3 + CD8 + T cells and CD56 + NK cell counts which disagreed with our findings.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of peripheral lymphocyte subsets' alteration and IL6 serum level correlated with Severity and outcome in Corona virus disease 2019 (COVID-19)

Elhady

Elrahman

Elsheikh

et al. 2021

Microbes and Infectious Diseases

View full text Add to dashboard Cite

Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain

Cited by 37 publications

References 47 publications

Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia

Predictors of Mortality Among Hospitalized COVID-19 Patients at a Tertiary Care Hospital in Ethiopia

A comprehensive evaluation of early potential risk factors for disease aggravation in patients with COVID-19

Evaluation of peripheral lymphocyte subsets' alteration and IL6 serum level correlated with Severity and outcome in Corona virus disease 2019 (COVID-19)

Contact Info

Product

Resources

About